Reddit Posts
Beware of penny stocks with poor fundamentals
Q4 Momentum Map - 5 small caps where story meets tape
Butterfly Network ($BFLY): From Device to Platform
$BFLY closed up almost 15%…up even further in AH/pre-market
$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms
$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms
$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms
$504 Billion AI Healthcare Revolution Accelerates as Corporate Giants Launch Next-Gen Platforms
Looking for Solid Sub-$10 Stocks to Hold Long-Term – What’s Still Undervalued Out There?
BFLY ready to fly like the beautiful butterfly it is.
MedTech Companies I’m Excited to Watch in 2024: $SHLT $BFLY $ME $ISRG
$BFLY Gaining Momentum as Cathie Wood Scoops Up 2 Million Shares for ARKK
$BFLY IS TAKING OFF AS CATHIE WOOD SCOOPS UP 2 MILLION SHARES FOR ARKK
What’s your Opinion on BFLY Butterfly Networks
I always knew if be a BFR when I grew up. Still long $AMWL, $BFLY, $TLRY, $MMND tho.
Triple yolo triple loser BFLY, HYLN, DM
These are the bags that I am holding. Which ones do you think I should retire, and which ones I DCA down?
HCAQ Hyperfine DD- the portable MRI following in BFLY’s footsteps
Hyperfine (HCAQ) DD the portable MRI, FDA cleared and already in the field
Hyperfine (HCAQ) Deep Dive taking off after merger. Portable MRI FDA approved
HCAQ Hyperfine DD and why it’s a high conviction play
$BFLY spotted on Inspiration4 live crew transmission!!! Next stop... The Moon.
Just saw $BFLY on Inspiration4. First all civilian flight. Next stop... To the moon!!! Lessgooooo!!!
Mentions
sold BFLY wayyy too early :cry:
Lol. So you're willing tk risk $20? And expect dell above 490? How about... 460/480 vertical for $7? 200% upside at 480. Breakeven at 467. If it goes down might buy back 490 and wait it out. Or, BFLY: 470/500/530 for $5. I'm getting same call at 4x less cost. 2x500 brings same $20 of credit and $530 for $5 caps the risk. But obviously you should get expensive otm calls and not hedge em.
BFLY Portable ultrasound with AI tools built in. Already adopted in ambulances for first responder use around the country. Sale and and licensing of their Ultrasound-on-chip infrastructure Recently announced partnership with Midjourney and their jointly-created full body ultrasound scanner that scans the entire body with Ultrasound-on-chip technically in 60 seconds. First scanner available 2027, but check out the video of the prototype. They are very communicative and what's going on with the company, which I might value most of all. So much more...
$CLS $BFLY $AVGO let's ride baby
My indicators are saying $BFLY is a massive buy rn, anyone else coming to this conclusion?
Seems to be a rotation into Biotech (shudder). I’m doing XBI cause I hate touching that stuff. I’ll do stuff on the more tech side of the ledger. I got lucky and caught BFLY. Now waiting for consolidation before going back in with that one. I don’t touch anything that’s Pharma unless it’s mega cap.
Guys it was just a quarterly rebalance has no bearing on next week at all. That being said. Stocks with some potential after today's move and the rebalance buys: SNOW, DDOG, TXG, BFLY, HOOD,
all aboard the BFLY rocketship guys
Try BFLY and watch it fly!
#TLDR --- Ticker: BFLY Direction: Up Prognosis: Buy shares at $4.20 (*nice*) before April 30th earnings Catalyst: OpenAI/Sam Altman are using their tech to build a non-invasive AI brain-machine interface Lobotomy Risk: 0% (Unlike Neuralink, no needles stabbing your brain required)
Doctor here. If you want a good long term play on anything medical, it’s BFLY. If you want to short anything, it’s def anything and everything drugs/peptides. Good luck fellow regards
The strategy BFLY articulated a year ago seems to have kicked in nicely here. Their numbers are shifting strongly in the right direction. For those who don’t know, they have a dramatically less expensive ultrasound that fits in your pocket and works with your smart phone. It’s cheap enough that any HCW and student can have one. A year ago they had high burn rate after developing the new gen devices. They articulated a plan to keep selling the improved devices cheaply and make profits on high margin software subs. The quarter reported yesterday shows exactly that. They’re still not profitable, but now getting very close thanks to growing and high margin software segment. The burn rate is slashed so if you project their inflection from loss to profit, the cash on hand appears to be enough to get there. They still have to execute and the plan has to sustain of course. But until two days ago, it was just theoretical that this strategy could work.
I’ve been waiting for BFLY to bounce and here is it. They were featured on the Survivor premiere yesterday. Also had some very prominent placement on The Pitt. Whoever is doing their media integration is crushing it.
BFLY for yolos. Made 30% and got out. Lots of volatility
Kraken Robotics, PCT, BFLY, AUR, but honestly, nothing as compelling as ASTS or RKLB were back then that I've seen.
RCAT, ONDS, BFLY Also check TMC but highly speculative and dependent on US government approving permits. NFA
Split it among CRMD, BFLY and PFE and write monthly calls on PFE.
I'm up +83% on BFLY. I don't even know wtf the company is. Does it have more potential?
BFLY. Dominating a unique market niche (portable medical ultrasound) with increasing name recognition and hospital system integration.
I've never heard of BFLY, why do you like it?
BFLY and WRBY for me, thanks!
buying BFLY dips are free money
BFLY constantly going up
BFLY bounced off 4hr support🙏🏼
BFLY triple blue diamond set up on the 4h, daily, and weekly. Reading up more on them tonight
didn’t buy FGL at .4 completely forgot about it, did start accumulating some BFLY. Companies financials are improving and the chart setup looks good.
BFLY = AI + Healthcare. Ya'll want in on this rocket?
Is BFLY a moonable stock or is it just destined for single digits?
BFLY over 500mil mc lets go bois they just had a decent earning report
Who are the competitors to BFLY? I bought BFLY on a whim (I'm a nurse), but I am no longer in the clinical setting, so I really don't know the space very well.
I worked for their direct competitor - actually the company that the ceo left to go start BFLY. Their product is superior, their customer experience is superior. The only thing is that, this isn’t exactly a money making product, and revenue cycles are super slow. Could be a good long term investment - I just don’t like how much supply there is.
Who else is in on BFLY? I feel like it has had some great recent news, but curious to know how others feel
I don’t know. There’s lots of reasons people sell. Another rising penny stock is BFLY.
What do you guys think of $BFLY
$BFLY - This company has an affordable portable ultrasound that is making a difference in health care settings. Time magazine recently recognized them as one of the World's Top Health Tech companies.
Who else is watching BFLY? Some interesting movement today, up 17% currently and am curious if I'm missing some news.
I bought BFLY $18 & lost my shirt. They’re not partnered with NVDA-last time I checked
Kicking around BFLY and LVO as short ish term plays. Anyone got thoughts?
Butterfly Network (BFLY) Analysis: Volatile Dip and Investment Thesis As of September 11, 2025, BFLY closed at $1.55, down approximately 22% from its recent high of $1.99 on August 5, 2025 (based on historical price data from Yahoo Finance and Nasdaq, reflecting a post-Q2 earnings pullback and broader medtech sector weakness). This decline was exacerbated by insider selling (e.g., Chief Business Officer Steven Cashman sold ~$214,000 worth of shares on September 9, 2025, per SEC filings), ongoing dilution concerns from a January 2025 public offering that priced shares at a discount (leading to a 15% immediate drop), and a 12.1% plunge on July 16, 2025, tied to weaker-than-expected sector news on healthcare spending cuts amid stagflation fears. Additional pressures include high short interest (9.85% of float as of August 29, 2025) and competition in portable ultrasound from players like Clarius and Mindray. Despite the volatility, analysts maintain a “Buy” consensus (from 6 firms, including TD Cowen at $3.50 and UBS at $2.25, initiated September 11, 2025), with an average 12-month price target of $3.17 (range $2.00–$4.00), implying 105% upside potential. This frames the dip as a speculative entry for high-risk investors, but with elevated volatility (beta 2.52) and execution risks in scaling AI-integrated devices amid regulatory hurdles. Below, I apply the same fundamental principles from the prior analysis to BFLY, adapting the structure for a single stock. This includes retail allocation, stock division metrics (detailed without skipping), buy order impact, macro alignment/growth/returns, investment ranking (within its sector), and alternatives. Data is sourced from the latest available metrics as of September 11, 2025 (e.g., Q2 2025 filings, Yahoo Finance, Nasdaq, Seeking Alpha), using historical proxies for forward estimates where needed. Background deep dive: Founded January 25, 2011, by Jonathan M. Rothberg, Ph.D. (a serial biotech entrepreneur with prior successes at 454 Life Sciences, acquired by Roche for $125M in 2007, and GeneDx, which went public via SPAC in 2021), Butterfly Network pioneered chip-based ultrasound to “democratize medical imaging.” Headquartered in Burlington, MA, the company went public via SPAC merger with Longview Acquisition Corp. on August 16, 2021, raising $175M from partners like Tenet Healthcare and UPMC. Key milestones include FDA clearance for iQ+ in 2021, enterprise rollout in 2023, and AI integrations like Butterfly Garden (launched 2024, with 2 new partners in Q2 2025: iCardio and HeartFocus). Leadership includes CEO Joseph M. DeVivo (since 2022, ex-GE Healthcare, compensation $2.25M in 2024), CTO Victor Ku (appointed September 9, 2025, ex-Apple AI hardware lead), CFO Heather C. Getz ($2.64M comp), and board members like Larry Robbins (Glenview Capital founder) and Dawn Carfora (ex-COO of Hologic). Success projects: Over 145,000 devices shipped globally by Q2 2025; partnerships with University of Rochester Medical Center (deployed 500+ iQ units for emergency use since 2022), Atrium Health (fleet-wide integration in 2024, reducing diagnostic times by 40%), Medical University of South Carolina (MUSC Blueprint platform for 1,000+ clinicians since 2023), Indiana University School of Medicine (curriculum integration for 2,000 students, improving ultrasound proficiency by 25% per internal studies), and recent Sientra partnership (July 2025) for in-office plastic surgery imaging. Q2 2025 revenue hit $23.4M (9% YoY growth, 63% gross margins—company record), with 35% Q4 2024 growth to $22.4M, but net loss narrowed 59% to -$0.06 EPS. Challenges: Cumulative losses ($500M+ since inception), high R&D burn ($40M quarterly), and a January 2025 offering diluting shares by 18.4% YTD. BFLY aligns robustly with US/world futures, revolutionizing diagnostics via AI-powered portable ultrasound (iQ series: whole-body, probe-only scanner at ~$2,400/unit vs. $50K+ cart-based). In 2025’s context of cooling inflation (Fed cuts to 4.5% aiding healthcare capex) and stagflation risks (tight budgets delaying adoptions), BFLY benefits from US priorities like telehealth expansion (post-COVID, $50B market by 2030) and global health equity (WHO goals for imaging access in low-resource areas). A strong dollar eases component imports (chip tech from Taiwan), but export hurdles to EMs persist; BFLY’s 60% US revenue mitigates via domestic focus. Global trends: AI diagnostics boom (projected 25% CAGR to $200B by 2030) and aging populations (UN: 1.5B over-60 by 2050) drive demand for point-of-care tools. Not financial advice as well as AI generated to clean up my thoughts
BFLY on the up, can we mention that one?
I’m also long on BFLY and MBOT. Both have incredible cost saving potential for hospitals.
BFLY hope it continues its run
I'd look into ARAY or BFLY. Medical devices are in the biotech world. Some are actually feasible companies, making real medical equiptment, as opposed to companies trying to make drugs for impossible cures, or going through drug phase trials.
BFLY named to TIME's list of the World's top 10 HeathTech companies 2025!
BFLY was named to TIME's list of the World's top 10 HeathTech companies 2025
Butterfly Network (BFLY) Analysis: Volatile Dip and Investment Thesis As of September 11, 2025, BFLY closed at $1.55, down approximately 22% from its recent high of $1.99 on August 5, 2025 (based on historical price data from Yahoo Finance and Nasdaq, reflecting a post-Q2 earnings pullback and broader medtech sector weakness). This decline was exacerbated by insider selling (e.g., Chief Business Officer Steven Cashman sold ~$214,000 worth of shares on September 9, 2025, per SEC filings), ongoing dilution concerns from a January 2025 public offering that priced shares at a discount (leading to a 15% immediate drop), and a 12.1% plunge on July 16, 2025, tied to weaker-than-expected sector news on healthcare spending cuts amid stagflation fears. Additional pressures include high short interest (9.85% of float as of August 29, 2025) and competition in portable ultrasound from players like Clarius and Mindray. Despite the volatility, analysts maintain a “Buy” consensus (from 6 firms, including TD Cowen at $3.50 and UBS at $2.25, initiated September 11, 2025), with an average 12-month price target of $3.17 (range $2.00–$4.00), implying 105% upside potential. This frames the dip as a speculative entry for high-risk investors, but with elevated volatility (beta 2.52) and execution risks in scaling AI-integrated devices amid regulatory hurdles. Below, I apply the same fundamental principles from the prior analysis to BFLY, adapting the structure for a single stock. This includes retail allocation, stock division metrics (detailed without skipping), buy order impact, macro alignment/growth/returns, investment ranking (within its sector), and alternatives. Data is sourced from the latest available metrics as of September 11, 2025 (e.g., Q2 2025 filings, Yahoo Finance, Nasdaq, Seeking Alpha), using historical proxies for forward estimates where needed. Background deep dive: Founded January 25, 2011, by Jonathan M. Rothberg, Ph.D. (a serial biotech entrepreneur with prior successes at 454 Life Sciences, acquired by Roche for $125M in 2007, and GeneDx, which went public via SPAC in 2021), Butterfly Network pioneered chip-based ultrasound to “democratize medical imaging.” Headquartered in Burlington, MA, the company went public via SPAC merger with Longview Acquisition Corp. on August 16, 2021, raising $175M from partners like Tenet Healthcare and UPMC. Key milestones include FDA clearance for iQ+ in 2021, enterprise rollout in 2023, and AI integrations like Butterfly Garden (launched 2024, with 2 new partners in Q2 2025: iCardio and HeartFocus). Leadership includes CEO Joseph M. DeVivo (since 2022, ex-GE Healthcare, compensation $2.25M in 2024), CTO Victor Ku (appointed September 9, 2025, ex-Apple AI hardware lead), CFO Heather C. Getz ($2.64M comp), and board members like Larry Robbins (Glenview Capital founder) and Dawn Carfora (ex-COO of Hologic). Success projects: Over 145,000 devices shipped globally by Q2 2025; partnerships with University of Rochester Medical Center (deployed 500+ iQ units for emergency use since 2022), Atrium Health (fleet-wide integration in 2024, reducing diagnostic times by 40%), Medical University of South Carolina (MUSC Blueprint platform for 1,000+ clinicians since 2023), Indiana University School of Medicine (curriculum integration for 2,000 students, improving ultrasound proficiency by 25% per internal studies), and recent Sientra partnership (July 2025) for in-office plastic surgery imaging. Q2 2025 revenue hit $23.4M (9% YoY growth, 63% gross margins—company record), with 35% Q4 2024 growth to $22.4M, but net loss narrowed 59% to -$0.06 EPS. Challenges: Cumulative losses ($500M+ since inception), high R&D burn ($40M quarterly), and a January 2025 offering diluting shares by 18.4% YTD. BFLY aligns robustly with US/world futures, revolutionizing diagnostics via AI-powered portable ultrasound (iQ series: whole-body, probe-only scanner at ~$2,400/unit vs. $50K+ cart-based). In 2025’s context of cooling inflation (Fed cuts to 4.5% aiding healthcare capex) and stagflation risks (tight budgets delaying adoptions), BFLY benefits from US priorities like telehealth expansion (post-COVID, $50B market by 2030) and global health equity (WHO goals for imaging access in low-resource areas). A strong dollar eases component imports (chip tech from Taiwan), but export hurdles to EMs persist; BFLY’s 60% US revenue mitigates via domestic focus. Global trends: AI diagnostics boom (projected 25% CAGR to $200B by 2030) and aging populations (UN: 1.5B over-60 by 2050) drive demand for point-of-care tools. Not financial advice as well as AI generated to clean up my thoughts
'Bout time BFLY flew 🦋 Now get me to break-even, pls 🙏
What’s going on with the spike on BFLY? Up 22% today
I’ll keep an eye on it. I think for the same price point- BFLY has better short term return potential. With HUMA, did they not schedule any appointments or presentations? Isn’t that normal for a rep to do? Maybe if they aren’t doing that is why there is a slower adoption rate. As far as this tech goes, how often would a VA hospital or a hospital your size go through in a month? What are the prices?
Laughing, I still remember when she loaded up on SKLZ and BFLY. All you had to do was look at balance sheet and could see they were burning cash. It told me that no one in her organization knew how to read a balance sheet.
How about BFLY? Seems like that might be the next big pumper
What's up Gloomy, thank you for the great posts man. If people listened to you a few months ago they would've been rich by now. If the technicals look great, as you say, I think for sure. With the closing of some Planned Parenthoods in the Bay Area, I think this will drive more of the female health, bio, med, tech, pharma. What do you think about these (BFLY, FEMY). Yahoo profile says INTS and breast cancer (breast cancer affects men too but largely focused on the ladies). But being bio tech pharma, Idk, what do you think.
$BFLY did amazing on earnings and dropped 17% 🤔🤔hedge funds are winning
BFLY moovin before earnings in the AM
What do we think about BFLY earnings?
ASNS - down BFLY - down CXAI - down DFLI - down NXDR - down SDST - down SNES - down Hahah all down except STAI! Not a great hit rate 😂
I read a study done where they gave specialists 6 different handheld ultrasound devices and tested the imaging of different spots and BFLY's product was ranked almost the lowest among them. I want to like this stock but im struggling to see the catalyst that will cause a bull run.
AI medical imaging device stock: $BFLY hasn't ran yet
BFLY 🦋….Earnings soon, tiny market cap, real tech, ran to nearly $5 this year…loading before volume returns. This one’s next 🦋
$BFLY dawg growing revenue, 150mil cash, hasn't ran yet
BFLY saw a good gain so far today, biomedical always popping off
oh now we're doing BFLY...ok
🦋Im new here, but $BFLY looks interesting…🦋
Outside of BFLY, I do not know anything about the others but looking quickly they appear to be big time dogs. For BFLY, similarly has been a long term slide stabilizing around $2. It is essentially a one product medical device company that will never compete against the majors. It was a Cathie Wood darling stock and not worth investing in in my opinion. If you want a speculative stock, maybe look at MVST. A small battery company that actually has revenue and products for the buses, trucks and heavy equipment market
You're understanding the basis of what a Call/Put Option is. You bought a $3.50 call on BFLY dated July 18th. You're expected the stock price to rise above $3.50 and the call you hold allows you to purchase 100 shares at $3.50 = $USD 350 or $CAD 500. When everyone else does it it's because they're capitalizing on the Delta and Gamma of the option and selling the option for a higher price. If BFLY rises to $4 before July 18th, your call option would increase in value since the option allows you to buy the shares for $3.50 instead of $4. To make money, you would then sell your call option to capture the rising value of the option. [What Is Options Trading? A Beginner's Overview](https://www.investopedia.com/options-basics-tutorial-4583012) This is an investopedia link on the basics of options. Read it.